| 1. |
- Abat, E., et al.
(författare)
-
Study of the response of the ATLAS central calorimeter to pions of energies from 3 to 9 GeV
- 2009
-
Ingår i: Nuclear Instruments & Methods in Physics Research. Section A: Accelerators, Spectrometers, Detectors, and Associated Equipment. - : Elsevier BV. - 0167-5087 .- 0168-9002 .- 1872-9576. ; 607:2, s. 372-386
-
Tidskriftsartikel (refereegranskat)abstract
- A fully instrumented slice of the ATLAS central detector was exposed to test beams from the SPS (Super Proton Synchrotron) at CERN in 2004. in this paper, the response of the central calorimeters to pions with energies in the range between 3 and 9 GeV is presented. The linearity and the resolution of the combined calorimetry (electromagnetic and hadronic calorimeters) was measured and compared to the prediction of a detector simulation program using the toolkit Geant 4. (C) 2009 Elsevier B.V. All rights reserved.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Constantinescu, O., et al.
(författare)
-
Two parasitic fungi on a new host, Syringa (Oleaceae)
- 2006
-
Ingår i: Mycotaxon. ; 94, s. 175-179
-
Tidskriftsartikel (refereegranskat)abstract
- Thedgonia ligustrina, the agent of Ligustrum leaf-spot, and Gloeosporidiella turgida, known as a parasite of Fraxinus, are reported for the first time on Syringa spp. Both fungi were found in Sweden, the first in a tree nursery in the south, and the second on plants cultivated in Uppsala. Brief descriptions and illustration are provided and the distribution of T. ligustrina is reviewed.
|
|
| 5. |
|
|
| 6. |
- Kappos, L., et al.
(författare)
-
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
- 2006
-
Ingår i: Neurology. - 1526-632X. ; 67:6, s. 944-953
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To conduct systematic long-term follow-up (LTFU) of patients in the Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis ( PRISMS) study to provide up to 8 years of safety, clinical and MRI outcomes on subcutaneous (SC) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS). Methods: The original cohort of 560 patients was randomized to IFN beta-1a, 44 or 22 mu g three times weekly (TIW) or to placebo; after 2 years, patients on placebo were rerandomized to active treatment and the blinded study continued for a further 4 years. The LTFU visit was scheduled 7 to 8 years after baseline. Results: LTFU was attended by 68.2% of the original PRISMS study cohort ( 382/560 patients). 72.0% (275/382) were still receiving IFN beta-1a SC TIW. Patients originally randomized to IFN beta-1a 44 mu g SC TIW showed lower Expanded Disability Status Scale progression, relapse rate and T2 burden of disease up to 8 years compared with those in the late treatment group. Brain parenchymal volume did not show differences by treatment group. Overall, 19.7% of patients progressed to secondary progressive MS between baseline and LTFU (75/381). No new safety concerns were identified and treatment was generally well tolerated. Conclusions: Despite the limitations inherent in any long-term study ( for example, potential differences between returning and nonreturning patients), these results indicate that patients with relapsing-remitting multiple sclerosis can experience sustained benefit over many years from early interferon beta-1a subcutaneous therapy three times weekly compared with patients whose treatment is delayed. This effect was more apparent in the patients receiving the higher dose.
|
|
